{"id":"insulin-lispro-protamine-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":{"setId":"e49f701d-c19f-4cb2-b63f-01a917b33abc","title":"INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION MIX75/25 KWIKPEN (INSULIN LISPRO) INJECTION, SUSPENSION [ELI LILLY AND COMPANY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro is a rapid-acting insulin analog that is combined with protamine to create a suspension that extends its duration of action to provide basal (background) insulin coverage. The protamine delays absorption of the insulin lispro, allowing it to work over approximately 24 hours. This formulation helps maintain steady glucose control between meals and overnight in patients with diabetes.","oneSentence":"Insulin lispro protamine suspension is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and storage, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:24.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01613807","phase":"PHASE4","title":"Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-10","conditions":"Gestational Diabetes Mellitus","enrollment":40},{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT01175811","phase":"PHASE4","title":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT00666718","phase":"PHASE3","title":"A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":374},{"nctId":"NCT01336751","phase":"PHASE3","title":"Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-07","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT00560417","phase":"PHASE3","title":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Diabetes Mellitus, Type 2","enrollment":339},{"nctId":"NCT00487240","phase":"PHASE3","title":"Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 1","enrollment":387},{"nctId":"NCT00510952","phase":"PHASE3","title":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-08","conditions":"Diabetes Mellitus, Type 2","enrollment":471},{"nctId":"NCT00494013","phase":"PHASE3","title":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-08","conditions":"Diabetes Mellitus Type 2","enrollment":442}],"_emaApprovals":[],"_faersSignals":[{"count":16,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":15,"reaction":"VOMITING"},{"count":12,"reaction":"DRUG INEFFECTIVE"},{"count":12,"reaction":"HEPATIC ENZYME INCREASED"},{"count":11,"reaction":"ARTHRALGIA"},{"count":11,"reaction":"SWELLING"},{"count":11,"reaction":"THERAPEUTIC RESPONSE DECREASED"},{"count":10,"reaction":"GAIT DISTURBANCE"},{"count":10,"reaction":"OEDEMA PERIPHERAL"},{"count":10,"reaction":"PAIN IN EXTREMITY"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY275585[P]","Insulin Lispro Protamine Suspension (ILPS)","Neutral Protamine Lispro (NPL)","Humalog","ILPS"],"phase":"marketed","status":"active","brandName":"Insulin Lispro Protamine Suspension","genericName":"Insulin Lispro Protamine Suspension","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro protamine suspension is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and storage, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}